Pollen Allergy Market Size to Surpass USD 5.8 Billion by 2036, Driven by Rising Disease Burden, Immunotherapy Advancements, and Emerging Biologic Therapies | DelveInsight

Posted on
by

Pollen Allergy Market Size to Surpass USD 5.8 Billion by 2036, Driven by Rising Disease Burden, Immunotherapy Advancements, and Emerging Biologic Therapies | DelveInsight
The Pollen Allergy Market is projected to grow significantly through 2036, driven by the rising prevalence of seasonal allergic rhinitis, increasing allergen exposure, and greater adoption of allergen immunotherapy. Advancements in biologics, including REGN5713-5715, along with improved molecular diagnostics and personalized treatment strategies, are expected to enhance disease management and support the expansion of the Pollen Allergy Treatment Market.

DelveInsight, a leading market research and healthcare consulting company, has released its latest report, “Pollen Allergy Market Insights, Epidemiology, and Market Forecast–2036.” The report provides a comprehensive understanding of Pollen Allergy, including historical and forecasted epidemiology, current and emerging treatment landscape, Pollen Allergy Market Trends, competitive intelligence, and forecasted market dynamics across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways from the Pollen Allergy Market

  • The Pollen Allergy Market Size across the 7MM is expected to grow substantially during the forecast period 2022–2036.

  • DelveInsight estimates that the Pollen Allergy Market Size will increase from approximately USD 3.7 billion in 2022 to nearly USD 5.9 billion by 2036, highlighting significant commercial opportunities within the Pollen Allergy Drug Market.

  • The United States accounted for the highest Pollen Allergy Market Share among the 7MM in 2025 and is expected to remain a key contributor throughout the forecast period.

  • Secondary research indicates that seasonal allergic rhinitis affects more than 80 million individuals in the United States, emphasizing the substantial disease burden and unmet need for effective therapies.

  • In Germany, hay fever affects more than 15% of the population, highlighting its widespread prevalence and growing public health impact.

  • In France, ragweed pollen allergy affects over 3.5 million people, creating a significant seasonal healthcare burden and demand for targeted treatment approaches.

  • According to secondary research, approximately 56.3% of pollen-sensitized patients in Japan demonstrate sensitization to ragweed pollen, underscoring the importance of allergen-specific management strategies.

  • Leading Pollen Allergy companies, including Regeneron Pharmaceuticals, ALK-Abelló, Merck, and Torii Pharmaceutical, are actively advancing innovative therapies to strengthen the future Pollen Allergy Industry.

  • Emerging therapies such as REGN5713-5715 are expected to reshape the future Pollen Allergy Treatment Market through targeted disease-modifying mechanisms.

Keen to know more about the market? Request our sample page for the Pollen Allergy Market.

https://www.delveinsight.com/sample-request/pollen-allergy-market

Key Factors Driving the Pollen Allergy Market

Rising Disease Prevalence and Environmental Exposure

Increasing exposure to environmental allergens, longer pollen seasons associated with climate change, and rising urbanization are contributing to the growing prevalence of pollen allergy worldwide. Enhanced awareness and diagnosis rates are further expanding the patient pool and driving Pollen Allergy Market Growth.

Growing Demand for Effective Pollen Allergy Treatments

The pharmacological treatment of pollen allergy primarily includes antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists, which help control symptoms such as sneezing, nasal congestion, and itchy eyes. Increasing patient demand for long-term disease control is supporting growth across the Pollen Allergy Drug Market.

Increasing Adoption of Immunotherapy and Personalized Care

Sublingual and subcutaneous allergen immunotherapies are increasingly being adopted due to their disease-modifying potential and ability to provide sustained symptom relief. Additionally, advances in molecular diagnostics, digital symptom-tracking tools, and personalized treatment strategies are emerging as key Pollen Allergy Market Trends.

Pollen Allergy Competitive Landscape

Several therapies currently shape the Pollen Allergy Treatment Market, including GRASTEK/GRAZAX (ALK-Abelló/Merck) and CEDARCURE (Torii Pharmaceutical). These therapies utilize allergen-specific immunotherapy approaches to induce long-term immune tolerance and reduce allergic responses.

Among emerging therapies, REGN5713-5715 from Regeneron Pharmaceuticals represents one of the most promising pipeline assets. This investigational monoclonal antibody combination targets the major birch pollen allergen Bet v 1 and aims to prevent allergen-IgE interactions, potentially offering rapid symptom relief and a novel disease-modifying approach for pollen-induced allergic rhinitis.

These advancements are expected to significantly influence future Pollen Allergy Market Share and strengthen the overall Pollen Allergy Industry outlook.

Discover more about therapies set to grab major Pollen Allergy market share @ Pollen Allergy Treatment LandscapeRecent Developments in the Pollen Allergy Market

  • In September 2025, Regeneron Pharmaceuticals reported positive Phase III results for REGN5713-5715 in patients with birch pollen allergy, demonstrating encouraging efficacy and a favorable safety profile.

  • Following these positive findings, Regeneron initiated registration-enabling studies in 2026, with topline data expected in 2027.

  • REGN5713-5715 is currently being evaluated in Phase III clinical trials for allergic conjunctivitis caused by birch pollen.

  • In December 2023, Torii Pharmaceutical entered into a licensing agreement with ALK-Abelló to obtain exclusive development and commercialization rights for GRAZAX in Japan.

What is Pollen Allergy?

Pollen allergy, also known as seasonal allergic rhinitis or hay fever, is an immune-mediated condition triggered by exposure to airborne pollen from trees, grasses, and weeds. Symptoms commonly include sneezing, nasal congestion, itchy eyes, fatigue, and sleep disturbances that can significantly impact daily activities and quality of life. Risk factors include genetic predisposition, family history of allergies, asthma, environmental pollution, and climate-related changes in pollen exposure.

Pollen Allergy Epidemiology Segmentation

The Pollen Allergy epidemiology section provides insights into the historical and current patient population and forecasted trends across the 7MM. The Pollen Allergy Market report offers epidemiological analysis for the study period 2022–2036 segmented into:

  • Total Diagnosed Prevalent Cases of Pollen Allergy

  • Age-specific Diagnosed Prevalent Cases of Pollen Allergy

  • Type-specific Diagnosed Prevalent Cases of Pollen Allergy

  • Treated Cases of Pollen Allergy

Scope of the Pollen Allergy Market Report

  • Therapeutic Assessment: Pollen Allergy current marketed and emerging therapies

  • Pollen Allergy Market Dynamics: Key Market Forecast Assumptions of Emerging Pollen Allergy Drugs and Market Outlook

  • Key Companies: Regeneron Pharmaceuticals, ALK-Abelló, Merck, Torii Pharmaceutical, and others

  • Key Therapies: REGN5713-5715, GRASTEK/GRAZAX, CEDARCURE, and others

  • Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

  • Unmet Needs, KOL Views, Analyst Views, Pollen Allergy Market Access and Reimbursement

To know more about Pollen Allergy companies working in the treatment market, visit @ Pollen Allergy Clinical Trials and Therapeutic AssessmentTable of Contents

  • Pollen Allergy Market Report Introduction

  • Executive Summary for Pollen Allergy

  • SWOT Analysis of Pollen Allergy

  • Pollen Allergy Patient Share (%) Overview at a Glance

  • Pollen Allergy Market Overview at a Glance

  • Pollen Allergy Background and Overview

  • Pollen Allergy Epidemiology and Patient Population

  • Country-Specific Patient Population of Pollen Allergy

  • Pollen Allergy Current Treatment and Medical Practices

  • Pollen Allergy Unmet Needs

  • Pollen Allergy Emerging Therapies

  • Pollen Allergy Market Outlook

  • Country-Wise Pollen Allergy Market Analysis (2022–2036)

  • Pollen Allergy Market Access and Reimbursement of Therapies

  • Pollen Allergy Market Drivers

  • Pollen Allergy Market Barriers

  • Pollen Allergy Appendix

  • Pollen Allergy Report Methodology

  • DelveInsight Capabilities

  • Disclaimer

  • About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/